Pre-hospital treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams. Expert position update 2022

Jacek Kubica1, Piotr Adamski1, Jerzy R. Ładny2, Jarosław Kaźmierczak3, Tomasz Fabiszak4, Krzysztof J. Filipiak4, Robert Gajda4, Mariusz Gąsiór4, Zbigniew Gąsiór7, Robert Gil8, Jarosław Gorący3, 9, Stefan Grajek10, Leszek Gromadziński11, Marcin Gruchała12, Grzegorz Grześk13, Piotr Hoffman14, Miłosz J. Jaguszewski12, Marianna Janion15, Piotr Jankowski16, 17, Zbigniew Kalarus18, Jarosław D. Kasprzak19, Andrzej Kleinrok20, Waclaw Kochman21, Aldona Kubica2, Wiktor Kuliczkowski22, Jacek Legutko23, Maciej Lesiak19, Klaudiusz Nadolny24, Eliano P. Navarese1, Piotr Niezgoda1, Małgorzata Ostrowska1, Przemysław Paciorek1, Jolanta Siller-Matula25, 26, Łukasz Szarpak27, 28, Dariusz Timler29, Adam Witkowski30, Wojciech Wojakowski31, Andrzej Wysokiński32, Marzena Zielińska33

1 Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland; 2 Department of Emergency Medicine, Medical University of Białystok, Poland; 3 Department of Cardiology, Pomeranian Medical University, Szczecin, Poland; 4 Institute of Clinical Medicine, Maria Skłodowska-Curie Medical Academy, Warsaw, Poland; 5 Gajda-Med. Medical Center, Pultusk, Poland; 6 Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland; 7 Department of Cardiology, Medical University of Silesia, Katowice, Poland; 8 Mossakowski Medical Research Institute, Polish Academy of Science, Warsaw, Poland; 9 Independent Laboratory of Invasive Cardiology, Pomeranian Medical University, Szczecin, Poland; 101st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland; 11 Department of Cardiology and Internal Medicine, School of Medicine, Collegium Medicum, University of Warmia and Mazury, Olsztyn, Poland; 121st Department of Cardiology, Medical University of Gdansk, Poland; 13 Department of Cardiology and Clinical Pharmacology, Faculty of Health Sciences, Nicolaus Copernicus University, Torun, Poland; 14 Department of Congenital Heart Defects, National Institute of Cardiology, Warsaw, Poland; 15 Institute of Medical Sciences, Collegium Medicum, Jan Kochanowski University, Kielce, Poland; 16 Department of Internal Medicine and Geriatric Cardiology, Center of Postgraduate Medical Education, Warsaw, Poland; 17 Department of Epidemiology and Health Promotion, School of Public Health, Center of Postgraduate Medical Education, Warsaw, Poland; 18 Chair and Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland; 191st Department of Cardiology, Medical University of Lodz, Bieganski Hospital, Lodz, Poland; 20 University of Information Technology and Management, Rzeszow, Poland; 21 The National Institute of Cardiology, Department of Cardiology, Bielski Hospital, Warsaw, Poland; 22 Institute of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland; 23 Department of Interventional Cardiology, Institute of Cardiology, Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland; 24 Faculty of Medicine, University of Technology in Katowice, Poland; 25 Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Poland; 26 Department of Cardiology, Medical University of Vienna, Austria; 27 Institute of Outcomes Research, Maria Skłodowska-Curie Medical Academy, Warsaw, Poland; 28 Research Unit, Maria Skłodowska-Curie Bialystok Oncology Center, Białystok, Poland; 29 Department of Emergency Medicine and Disaster Medicine, Medical University of Lodz, Poland; 30 Department of Interventional Cardiology and Angiology, National Institute of Cardiology, Warsaw, Poland; 31 Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland; 32 Department of Cardiology, Medical University of Lublin, Poland; 33 Department of Invasive Cardiology, Medical University of Lodz, Poland

Address for correspondence: Prof. Jacek Kubica, Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, ul. M. Skłodowskiej-Curie 9, 85–094 Bydgoszcz, Poland, e-mail: jkubica@cm.umk.pl

Received: 1.02.2022   Accepted: 24.04.2022   Early publication date: 28.04.2022

This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
Introduction

Recommendations for medical emergency teams regarding the pre-hospital management of patients with acute coronary syndrome (ACS) have been developed in 2017 by a broad representation of Polish experts in cardiology and emergency medicine [1]. These recommendations have been updated after the publication of the 2017 European Society of Cardiology (ESC) guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation (STEMI) and the 2017 update focused on dual antiplatelet therapy (DAPT) in coronary artery disease [2–4]. The 2020 ESC guidelines for the management of ACSs in patients presenting without persistent ST-segment elevation (NSTE-ACS) introduced several significant changes in treatment strategies [5]. The current expert position update aims to put the 2020 ESC guidelines into a Polish perspective and to provide practical recommendations for medical emergency teams.

Diagnosis and logistics of ACS patients

Emergency medical teams are responsible for early diagnosis, triage, transport and treatment of ACS patients [1–6]. In order to improve the quality of care and decrease adequate treatment delay, an early working diagnosis of ACS and risk stratification should be conducted at the earliest possible moment. The efficient treatment of ACS patients requires appropriate ambulance equipment and staff competences. All medical emergency system ambulances should be equipped with electrocardiogram (ECG) recorders, defibrillators, and at least one person trained in advanced life support. All ambulance personnel should be trained to recognize clinical symptoms of acute myocardial infarction (MI), record and transmit ECG, administer oxygen when appropriate, relieve pain, and provide basic life support [1, 2, 4].

Acute coronary syndrome may be associated with a wide variety of symptoms ranging from cardiac arrest, electrical or hemodynamic instability with cardiogenic shock due to ongoing ischemia or mechanical complications such as severe mitral regurgitation, to patients who are already pain free at the time of presentation. The major trigger for the diagnostic and therapeutic actions in patients with suspected ACS is acute chest discomfort, primarily characterized as pain, pressure, tightness, and burning. Chest pain-equivalent symptoms, such as dyspnea, epigastric pain or pain in the left arm, may also occur [5].

The resting 12-lead ECG is the first-line diagnostic tool in the assessment of patients with suspected ACS. It is recommended to perform it within 10 minutes after the first contact with the emergency medical services in a pre-hospital setting and to have it immediately interpreted by a qualified physician using remote technologies [1, 2, 4, 5].

The presence of persistent ST-segment elevation in two contiguous leads is considered one of the best indicators of ongoing MI with an occluded infarct artery [2]. If the standard leads are inconclusive, recording of additional leads (V7–V9 or V3R and V4R) should be performed as they can be the only ones to reveal left circumflex artery occlusion or right ventricular MI, respectively [5]. It is recommended to manage subjects with typical clinical symptoms of ongoing myocardial ischemia and left bundle branch block (LBBB) similar to STEMI patients, regardless of whether the bundle branch block has been previously known [2, 5]. In patients with right bundle branch block the interpretation of electrocardiographic changes is more specific as ST-elevation is indicative of STEMI, while ST-segment depression in lead I, AVL, and V5–V6 is indicative of NSTE-ACS [5]. Primary percutaneous coronary intervention (PCI) strategy is also recommended in the setting of other atypical electrocardiographic presentations combined with ongoing symptoms suggestive of myocardial ischemia, including: ventricular paced rhythm (during right ventricular pacing, the ECG shows LBBB pattern), isolated posterior MI (isolated ST depression > 1 mm in leads V1–V3 and ST-segment elevation ≥ 0.5 mm) in posterior chest wall leads V7–V9, ischemia due to left main coronary artery occlusion or multivessel disease (ST-segment depression ≥ 1 mm in 6 or more surface leads, coupled with ST-segment elevation in aVR and/or V1) [2, 5]. Characteristic ECG features of NSTE-ACS include ST-segment depression, transient ST-segment elevation, and T-wave changes however, ECG may remain normal in more than 30% of patients [5].
The ECG monitoring should be applied immediately in all patients with initial diagnosis of ACS in order to detect life-threatening arrhythmias and allow prompt defibrillation, if indicated [1, 2, 4].

Acute coronary syndromes are characterized by high clinical instability, therefore patients with initial diagnosis of ACS, even those who are not candidates for immediate coronary angiography and subsequent PCI at the time of initial diagnosis, should be transported to centers with invasive cardiology facilities regardless of changes in ECG [2, 5, 7–9]. Nevertheless, teleconsultation including transmission of patients’ 12-lead ECG and clinical data to the destination center should be performed at the first medical contact [1, 2, 4, 10]. Teleconsultation, apart from the preliminary diagnosis and logistics aspects, should be used to coordinate pre-hospital therapy, especially regarding antiplatelet therapy and unfractionated heparin. This strategy is aimed to reduce treatment delay leading to mortality reduction in STEMI and very high-risk NSTE-ACS patients. This allows immediate activation of the interventional team and direct transportation of patients triaged for a primary PCI strategy to the catheterization laboratory, bypassing the emergency department [1, 2, 4, 11]. Therefore, the medical emergency system dispatcher should not change the choice of the destination center, unless, in his opinion, the choice made by the emergency medical team is incorrect. In this case, the change and its justification must be documented.

In locations where there is more than one hospital with an invasive cardiology unit, the selection of the destination center should be based both on the patient’s clinical status and center category depending on its level of preparation for treatment of ACS patients. Local categorization of centers should take into account the following factors: the availability of invasive cardiology and cardiac surgery in one location, the number of cath labs available, the availability of hybrid rooms and circulatory support systems, and the number of beds in the intensive coronary care unit. Generally, ACS patients qualified for the immediate invasive strategy should be transferred to the nearest PCI center, however, whenever possible, direct transport of the highest risk patients (STEMI, NSTE-ACS of very high-risk, cardiogenic shock) to centers with both invasive cardiology and cardiac surgery facilities should be considered. It should be stressed however, that preference for this category of hospitals must not cause delay of invasive diagnostics [1, 4, 12].

Centers participating in the Managed Care after Acute Myocardial Infarction (KOS-zawal) network should be preferred as the target destination for all ACS patients due to comprehensive post-hospitalization care they provide. To ensure high quality of care in ACS patients, a working diagnosis, pivotal statements, decisions, medications, and time-points should be registered and monitored. Periodic evaluation at the local level (city/voivodeship) should cover the correctness of the initial diagnosis and treatment, the duration and causes of delays related to transport, diagnosis and treatment, the quality of cooperation between the emergency medical teams and hospital staff, and the target center choice correctness [2].

**Chest pain management**

Coronary revascularization is the most efficient analgesic treatment in patients with acute myocardial ischemia, regardless of ACS type. Patients presenting with STEMI or NSTE-ACS with recurrent or refractory chest pain despite medical treatment should be qualified to immediate invasive strategy [2, 5]. However, even in the most developed medical emergency systems with an access to extensive network of 24/7 PCI centers, the delay between the first medical contact and coronary revascularization may reach tens of minutes contributing to a prolonging chest discomfort. In order to cover the time until the culprit vessel is treated, a potent analgesic with a quick onset of action is necessary to provide timely and effective pain blockade.

The latest ESC guidelines on the treatment of STEMI recommend to titrate intravenous opioids to relieve pain in the pre-revascularization stage in patients with ongoing chest pain. Currently this constitutes a class IIa recommendation (“should be considered”) with a level of evidence C (“consensus of the opinion of the experts and/or small studies, retrospective studies, registries”) [2]. Notably, this recommendation has been downgraded from class I (“is recommended”) compared with the previous edition of the ESC guidelines on STEMI [2, 13]. The 2020 ESC guidelines for the management of NSTE-ACS do not contain any recommendations regarding analgesic pharmacotherapy with opioids in patients with NSTE-ACS [5]. The former edition of these guidelines also did not provide any official recommendation regarding this topic, however the authors stated, that administration of
opiods is reasonable in NSTE-ACS patients with sustained severe chest pain who are waiting for urgent coronary angiography [14]. In this group sublingual or intravenous nitrates and early initiation of beta-blocker treatment are indicated, if ischemic symptoms are ongoing [5]. On the other hand, in the acute phase of STEMI nitrates have failed to show benefit and are not recommended, unless they are required for the control of heart failure symptoms or hypertension [2, 15].

Abundant experience with the use of morphine, its analgesic potency and wide availability explain why it remains the most commonly administered analgesic in patients with MI [16]. Nevertheless, morphine may cause adverse effects, including bradycardia, hypotension, and impairment of the intestinal propulsive function or even suppression of the respiratory function [17]. Additionally, morphine leads to impaired absorption of orally administered antiplatelet drugs, delay of anti-aggregatory effect and its reduction [18]. Noteworthy, this issue not only concerns clopidogrel, but also the newer P2Y12 receptor antagonists prasugrel and ticagrelor [19–21]. Although some studies suggest that morphine use may be related to increased infarct size, reinfarction rate and mortality, data from registries are ambiguous and randomized trials on this matter are lacking [22–27]. A meta-analysis of mostly observational studies has reported no association between morphine use in patients undergoing primary PCI for STEMI and adverse short-term clinical outcomes [28].

Recently, fentanyl has been proposed as an alternative to morphine in ACS patients with chest pain. However, in the setting of PCI fentanyl, similarly to morphine, leads to impairment of ticagrelor bioavailability and delay in its antiplatelet effect suggesting a class effect regarding the opioid-P2Y12 receptor inhibitor interaction [29]. Also, there is no difference in inhibition of platelet reactivity in ACS patients during the first 2 hours after a ticagrelor loading dose, suggesting no pharmacodynamic benefit from using fentanyl instead of morphine [30]. Interestingly, intravenous acetylsalicyphen results in a comparable extent of pain relief when compared to fentanyl before and immediately after primary PCI for STEMI [31]. Still, although this approach increases the absorption of ticagrelor in patients with STEMI compared with fentanyl-treated patients, it does not improve the early antiplatelet response (before and just after primary PCI) [31]. Additionally, acetylsalicyphen lacks anxiolytic effect that may be advantageous in the early phase of ACS treatment.

Due to the potentially harmful effect of oxygen in uncomplicated MI patients it should be used only in hypoxic patients with arterial oxygen saturation (SaO₂) < 90% [2]. In summary, routine use of opioids in ACS should be avoided and restricted only to a selected group of patients with severe, refractory chest pain. In case analgesic treatment is needed, withdrawal from morphine use or a routine switch to either fentanyl or acetylsalicyphen should not be recommended. Due to reasons explained above morphine should remain the first choice analgesic in ACS. Nevertheless, it has to be underlined that administration of this opioid should be limited only to patients with severe chest pain, and that the dose should be titrated to the minimal effective dosage in order to limit potential adverse effects of the drug. The timing and dosage of administered morphine should always be recorded and communicated to the medical staff of the destination cardiology center. In order to counteract adverse effects of opioids on absorption and platelet inhibition in ACS, administration of crushed tablets of ticagrelor, prasugrel or clopidogrel should be considered due to previously demonstrated acceleration of absorption and antiplatelet effect onset of P2Y12 receptor inhibitors when given in crushed form [32–35]. Additionally, administration of intravenous metoclopramide in opioid-treated ACS patients may also be considered to enhance absorption of antiplatelet agents from the gastrointestinal tract [36].

**Antiplatelet treatment in ACS patients**

Dual antiplatelet therapy including acetylsalicylic acid (ASA) and one of the P2Y12 receptor inhibitors, remains a standard of care in patients with ACS [2, 3, 5, 37].

**ASA therapy in patients with ACS**

Acetylsalicylic acid is an irreversible inhibitor of platelet cyclooxygenase isoenzyme type 1. According to the current guidelines, administration of an oral, rapidly absorbed ASA formulation in a loading dose of 150–300 mg or 75–250 mg intravenous ASA (if oral ingestion not possible) is recommended in all ACS patients with no contraindications (class of recommendation I, level of evidence A) [2, 5, 37]. The treatment should be applied as early as possible, i.e. upon the first medical contact. Subsequently, all patients should
receive chronic therapy with ASA 75–100 mg q.d. [2, 3, 5, 37, 38].

**Platelet P2Y12 receptor inhibitors**

Currently, three platelet P2Y12 receptor inhibitors are available in Poland: clopidogrel, prasugrel, and ticagrelor. Unfortunately, cangrelor, the only intravenous rapidly acting P2Y12 receptor inhibitor recommended in the most recent ESC guidelines, is still unavailable. Clopidogrel and prasugrel are pro-drugs and require hepatic activation into active metabolites irreversibly binding to the P2Y12 receptor, whereas ticagrelor and cangrelor are active drugs, which directly and reversibly block this receptor. Prasugrel and ticagrelor are preferentially recommended over clopidogrel due to their faster, more potent, and more uniform anti-aggregation effect, translating into better clinical outcomes [2, 3, 5, 37, 38]. When starting the treatment with P2Y12 receptor inhibitors one should always be aware of contraindications for these drugs (Table 1). Both prasugrel and ticagrelor are contraindicated in patients with prior hemorrhagic stroke, severe liver disorder or those requiring chronic oral anticoagulation [2, 3, 5]. Moreover, prasugrel is also contraindicated in patients with a history of ischemic stroke or transient ischemic attack, it is generally not recommended for patients above 75 years of age or with body weight below 60 kg, but, if necessary, a reduced dose of 5 mg can be applied in these patients [2, 3, 5]. When neither of these agents is available or if they are contraindicated, clopidogrel should be administered instead [2, 3, 5]. Importantly, in ACS patients who were previously treated with clopidogrel or have received a loading dose of clopidogrel a switch to ticagrelor is indicated at a loading dose of 180 mg (class of recommendation I, level of evidence B) [37, 39].

Substantial percentage of ACS patients require long-term oral anticoagulation. The concomitant use of DAPT and oral anticoagulation increases the risk of bleeding complications 2- to 3-fold when compared to anticoagulation alone [40–43]. Clopidogrel is the only P2Y12 inhibitor to be used in combination with oral anticoagulants (acenocoumarol, apixaban, dabigatran, rivaroxaban, or warfarin) [2, 3]. Use of ticagrelor or prasugrel as a part of triple therapy is not recommended (class of recommendation III, level of evidence C) [2, 3, 5]. However, patients burdened with moderate-to-severe risk of stent thrombosis, who require concomitant oral anticoagulation may benefit from dual antithrombotic therapy comprising oral anticoagulant and prasugrel or ticagrelor instead of triple therapy (class of recommendation IIb, level of evidence C) [5].

Due to its rapid onset of action cangrelor appears to be the optimal P2Y12 receptor inhibitor for ACS patients requiring urgent invasive treatment [44, 45]. This compound may be considered in patients not pre-treated with oral P2Y12 receptor inhibitors at the time of PCI or in those who are considered unable to absorb oral agents, particularly in unconscious patients, patients with post-cardiac arrest syndrome, or patients treated with mild therapeutic hypothermia, when gastrointestinal absorption of medications is impaired [2, 5, 46–48]. Unfortunately, up to date cangrelor is not available in Poland.

In conservatively treated ACS patients ticagrelor is preferred over clopidogrel (class of recommendation IIa, level of evidence C), while prasugrel is not indicated (class of recommendation III, level of evidence B) [3].

---

**Table 1. Contraindications for the use of P2Y12 receptor inhibitors in patients with acute coronary syndrome.**

| Contraindication                                         | Clopidogrel | Prasugrel | Ticagrelor | Cangrelor |
|-----------------------------------------------------------|-------------|-----------|------------|-----------|
| Hypersensitivity to the P2Y12 receptor inhibitor           | X           | X         | X          | X         |
| Active bleeding                                           | X           | X         | X          | X         |
| Severe liver disorder                                     | X           | X         |            |           |
| History of ischemic stroke                                | Within 7 days| X        |            | X         |
| History of transient ischemic attack                      | X           |           | X          |           |
| History of intracranial hemorrhage                         | X           | X         |            |           |
| Indication for chronic oral anticoagulation               | X           |           | X          |           |
| Prior administration of other P2Y12 receptor inhibitor     | X           |           | X          |           |
Platelet P2Y12 receptor inhibitors in the treatment of patients with STEMI

ST-segment elevation MI is usually a result of sudden and complete occlusion of a coronary artery. Such immediate interruption in oxygen supply to the heart leads to rapidly progressing myocardial necrosis. The main goal of STEMI treatment is to salvage as much cardiac muscle as possible, and this can be obtained by expeditious reperfusion of the culprit vessel, preceded by timely diagnosis and transportation to the catheterization laboratory without unnecessary delay. Primary PCI remains the mainstay of coronary revascularization in patients with STEMI [2]. According to the ESC guidelines pre-hospital fibrinolysis is indicated in patients presenting early when anticipated STEMI diagnosis to PCI-mediated reperfusion time is > 120 minutes [2]. Nevertheless, in the Polish reality, where the density of invasive cardiology facilities is very high and transport times are short, the probability of such a situation is negligible. Moreover, the use of fibrinolytic drugs in ambulances was not approved by the Directive of the Minister of Health of Poland [49].

In the clinical setting of STEMI both potent P2Y12 inhibitors, prasugrel or ticagrelor, are preferred over clopidogrel. The use of clopidogrel should be limited to situations when neither of the stronger P2Y12 receptor inhibitors is available or when they are contraindicated (class of recommendation I, level of evidence A) [2]. Currently there is no evidence from randomized controlled trials indicating the optimal time point for initiation of antiplatelet treatment in STEMI [2]. Nevertheless, the available data suggest early initiation of P2Y12 receptor inhibitor treatment in order to obtain effective platelet inhibition by the time of PCI, especially that administration of P2Y12 inhibitors in pre-hospital management is considered to be safe [2, 38]. Therefore, prasugrel 60 mg loading dose or ticagrelor 180 mg loading dose should be administered directly after the STEMI diagnosis is confirmed by ECG [2]. If unavailable or contraindicated clopidogrel 600 mg should be administered instead [2]. The ATLANTIC study has shown the pre-hospital loading with ticagrelor to be safe for STEMI patients [50]. Alternatively, in P2Y12-inhibitor naïve patients undergoing PCI cangrelor (intravenous bolus of 30 mg/kg with subsequent of 4 mg/kg/min infusion lasting at least 2 h or duration of procedure, whichever is longer) may be considered (class of recommendation IIb, level of evidence A) [37]. However, up to date cangrelor is not available yet in Poland. Pre-hospital administration of DAPT should be especially avoided if there is a suspicion of active bleeding, mechanical complications of MI, acute aortic dissection or any other co-morbidities requiring emergency surgical operation.

Platelet P2Y12 receptor inhibitors in the treatment of patients with NSTE-ACS

Urgent coronary reperfusion is a mainstay of treatment for patients with STEMI, while in patients with NSTE-ACS the indications and recommended timeframes for invasive diagnostics and treatment depend primarily on risk stratification [2, 5]. The available evidence indicates that a routine invasive strategy reduces the risk of the composite ischemic endpoints, particularly in high-risk patients. Nevertheless, a routine invasive strategy does not reduce all-cause mortality in the overall population of NSTE-ACS patients, and it increases the risk of periprocedural complications [5]. The results of randomized controlled trials and their meta-analyses highlight the role of risk stratification in the decision-making process and support a routine invasive strategy only in very high and high-risk patients [51–55].

According to the ESC guidelines, immediate invasive strategy (< 2 h) should be applied in very high-risk NSTE-ACS patients (i.e., with at least one very high-risk criterion) [5]. The NSTE-ACS very high-risk criteria are defined as follows:

- Hemodynamic instability;
- Cardiogenic shock;
- Recurrent/refractory chest pain despite medical treatment;
- Life-threatening arrhythmias;
- Mechanical complications of MI;
- Acute heart failure clearly related to NSTE-ACS;
- ST-segment depression > 1 mm/6 leads plus ST-segment elevation aVR and/or V1.

Early invasive strategy (< 24 h) is recommended in high-risk patients. The NSTE-ACS high-risk criteria are defined as follows:

- Established NSTEMI diagnosis;
- Dynamic or presumably new contiguous ST/\(^T\)-segment changes (symptomatic or silent);
- Resuscitated cardiac arrest without ST-segment elevation or cardiogenic shock;
- GRACE risk score > 140.

Similar to STEMI, DAPT, including ASA and one of the potent P2Y12 receptor inhibitors, is also recommended in patients with NSTE-ACS, unless
contraindicated, e.g., due to excessive bleeding risk (class of recommendation I, level of evidence A) [5]. The ISAR-REACT 5 trial compared two antiplatelet strategies: prasugrel-based vs. ticagrelor-based strategy in ACS patients for whom an invasive evaluation was planned. The trial demonstrated that the prasugrel-based strategy was associated with a reduced rate of composite of death, MI, or stroke, without an increase in the rate of bleeding complications [56]. Based on this single trial, the authors of the 2020 ESC guidelines on NSTE-ACS recommended prasugrel to be considered in preference to ticagrelor for NSTE-ACS patients who proceed to PCI after a diagnostic angiography was performed (class of recommendation IIa, level of evidence B) [5]. It should be highlighted, that the guidelines authors did not take into account serious limitations of the ISAR-REACT 5 trial [57–61] nor the results of the network meta-analysis of 12 randomized controlled trials by Navarese et al. [62] which clearly showed a similar reduction of ischemic events and increase of bleeding with both prasugrel and ticagrelor in comparison with clopidogrel. However, a significant mortality reduction was observed with ticagrelor only. Moreover, the meta-analysis showed that by excluding open label randomized controlled trials due to their limitations (e.g., ISAR-REACT 5), the mortality reduction with ticagrelor was strengthened without a significant increase of bleeding [62].

The 2020 ESC guidelines on NSTE-ACS suggest considering pre-treatment with a P2Y12 inhibitor in patients with NSTE-ACS who are not planned to undergo an early invasive strategy and do not have a high bleeding risk (class of recommendation IIb, level of evidence C) [5]. The same guidelines advocate against the use of routine pre-treatment with P2Y12 inhibitors in patients for whom coronary anatomy is not known and an early invasive management is planned (class of recommendation III, level of evidence A) [5].

In fact, supportive observations for a restrictive use of pre-treatment with P2Y12 receptor inhibitor are limited to prasugrel (ACCOAST trial) [63]. Therefore, prasugrel should not be administered prior to coronary angiography or when the patient is qualified for conservative treatment (class of recommendation III, level of evidence B) [37]. The prospective Swedish Coronary Angiography and Angioplasty Registry (SCAAR) [64] showed that pre-treatment of NSTE-ACS patients with P2Y12 receptor antagonists was not associated with improved clinical outcomes, but was associated with increased risk of bleeding in all consecutive patients who underwent PCI for NSTE-ACS (59894 patients with P2Y12 pre-treatment vs. 4963 patients without P2Y12 pre-treatment). However, whether pre-treatment with P2Y12 antagonists in selected high and very high-risk patients can improve clinical outcomes was not established in this study [64]. Moreover, the DUBIUS trial assessing efficacy and safety of pre-treatment vs. loading after angiography with oral P2Y12 receptor inhibitor in NSTE-ACS patients, was prematurely interrupted due to low incidence of ischemic and bleeding events and minimal numeric difference of event rates between the treatment groups [65].

According to the 2020 ESC guidelines, potent P2Y12 receptor inhibitors (ticagrelor or prasugrel) exhibit a fast onset of antiplatelet action, thereby allowing loading dose administration after diagnostic coronary angiography and directly before PCI [5]. However, the fast onset of action has been shown only in a stable setting [66–69], while in patients with MI the antiplatelet effect of both drugs was delayed, achieving satisfactory platelet inhibition in the majority of patients 2 hours after loading dose administration [17, 18, 70, 71]. Of note, even 4 hours after administration of the loading dose of ticagrelor high platelet reactivity (as assessed with VASP assay) was found in 7–37% of patients (depending on concomitant morphine administration) [17, 18, 70, 71]. Therefore, sufficient platelet inhibition at the time of PCI cannot be expected in patients in whom loading dose of ticagrelor or prasugrel was given after diagnostic coronary angiography and directly before PCI. This limitation can be overcome with cangrelor [5, 38, 44, 72, 73]. According to the ESC guidelines, due to its proven efficacy in preventing intra-procedural and postprocedural stent thrombosis cangrelor may be considered for use in P2Y12 receptor inhibitor-naive NSTE-ACS patients undergoing PCI (class of recommendation IIb, level of evidence A) [5, 37]. Unfortunately, cangrelor is still not available in Poland.

Due to conflicting evidence the routine pre-hospital administration of P2Y12 inhibitors in patients with NSTE-ACS is not recommended. However, even though early administration of P2Y12 receptor antagonists may increase the bleeding risk, the potential benefits for the selected NSTE-ACS patients may justify in-hospital administration of a ticagrelor loading dose before coronary angiography after an individual assessment. It has to be underlined though, that a decision on potential use of in-hospital pre-treatment...
with ticagrelor should be left to the discretion of the treating physician.

**Antiplatelet treatment after ACS**

Dual antiplatelet therapy with ASA and P2Y12 receptor inhibitor should be maintained for 12 months after ACS, unless contraindications exist (class of recommendation I, level of evidence A) [2, 5]. In specific clinical scenarios, the duration of DAPT can be shortened, extended (> 12 months) or modified considering individual ischemic and bleeding risk, the occurrence of adverse events, comorbidities, and co-medications [2, 5, 62, 74–76]. Adding a second antithrombotic drug to ASA for long-term secondary prevention should be considered in patients with a high risk of ischemic events and without high bleeding risk (class of recommendation IIa, level of evidence A) — as a dual antithrombotic therapy (DATT). This strategy may be also considered in patients with at least a moderately increased risk of ischemic events and without high bleeding risk (class of recommendation IIb, level of evidence A) [5, 77]. A greater benefit in post-ACS patients may be expected with ASA and ticagrelor 60 mg b.i.d. when the therapy is continued after 12 months of DAPT without interruption or with short interruption only. On the other hand, a combination of ASA and rivaroxaban 2.5 mg b.i.d. seems to be a better option when indications for DATT appear after a longer time from ACS (more than 2 years) and/or from cessation of DAPT (more than 1 year), and in patients with multiple vascular bed atherosclerosis [78].

**Conclusions**

Dual antiplatelet therapy composed of ASA and a P2Y12 receptor inhibitor remains a mainstay of ACS therapy. The ESC guidelines recommend the use of potent P2Y12 inhibitors — prasugrel or ticagrelor over clopidogrel in all ACS patients, unless contraindicated, e.g., due to an excessive risk of bleeding [2, 5]. Clopidogrel is reserved for situations when prasugrel or ticagrelor are not available, cannot be tolerated or are contraindicated. Indications for ticagrelor are wider as compared with prasugrel, because ticagrelor can be used in conservatively treated ACS patients, patients pre-loaded with clopidogrel or on chronic clopidogrel therapy, as well as in those with previous ischemic stroke or transient ischemic attack, elderly (> 75 years of age) or those with low body mass (< 60 kg) [2, 3, 5]. Although, limited data on optimal timing of the P2Y12 receptor inhibitor initiation exist, there is a consistent recommendation that early administration — at the time of diagnosis — of a potent P2Y12 receptor inhibitor together with ASA and heparin is crucial in the management of all patients with STEMI [2]. In patients presenting with NSTE-ACS the latest 2020 ESC guidelines do not recommend the routine pre-treatment with a P2Y12 receptor inhibitor in patients in whom coronary anatomy is not known and an early invasive management is planned (class of recommendation III, level of evidence A) [5]. But, since the full antiplatelet effect is desired at the time of PCI and rapidly acting intravenous cangrelor is unavailable in Poland, in-hospital administration of ticagrelor loading dose before coronary angiography may be justified after an individual assessment. The use of prasugrel is not advised when the coronary anatomy is unknown what makes ticagrelor the drug of choice in the majority of ACS patients [37]. Moreover, ACS patients pre-treated with clopidogrel should be switched to ticagrelor when not contraindicated, but not to prasugrel which is recommended only in P2Y12 receptor inhibitor-naïve patients [3]. Importantly, in ACS patients undergoing coronary artery by-pass grafting procedure the use of ticagrelor provides the best safety profile, reducing the risk of adverse cardiovascular events, including death, yet not increasing the risk of coronary artery by-pass grafting-related bleeding when compared with clopidogrel [79].

Since the publication of the previous Recommendations for medical emergency teams a new Directive of the Minister of Health dated December 16, 2019 has been published [49]. Paramedics and emergency medical team members are allowed to (after ECG tele-transmission and consultation with the physician evaluating the ECG) administer as previously only clopidogrel and ticagrelor; but not prasugrel. In the periprocedural period ACS patients require anticoagulant treatment apart from DAPT, and according to the above-mentioned Directive of the Minister of Health, unfractionated heparin (70–100 U/kg) is the only anticoagulant agent that can be administered by paramedics and emergency medical team members.

This expert position is not fully in line with the recently published expert opinion of the Association of Cardiovascular Interventions and the Working Group on Cardiovascular Pharmacotherapy of the Polish Cardiac Society [80]. Nevertheless, the aforementioned expert opinion is only a summary of the 2020 ECS guidelines [5], while the present position paper is a proposal for the
practical application of these recommendations in Polish conditions.

Pain management is an important part of the ACS emergency care. Titrated intravenous morphine remains the standard of care in STEMI patients [2]. While undertaking decision to administer morphine one should bear in mind the unwanted interaction between morphine and antiplatelet drugs as well as the fact that the most effective analgesic in ACS is urgent revascularization [17].

In the pre-hospital period patients with ACS may experience vomiting especially when given morphine. It carries the risk of loss of yet unabsorbed antiplatelet drugs. In such cases the time elapsed from drug intake to vomiting and the potential presence of tablets in the vomited content should be documented. The decision on administration of an additional dose of antiplatelet drugs should be left to the discretion of the physician at the destination hospital.

To conclude, ECG tele-transmission at first medical contact and consultation with experienced cardiologist enables pre-hospital administration of P2Y12 inhibitor loading dose added to ASA in all STEMI patients, while in NSTE-ACS patients in-hospital loading with P2Y12 inhibitor may be justified in selected patients (Fig. 1). Ticagrelor is the P2Y12 receptor inhibitor of choice in the vast majority of ACS patients.

**Conflict of interest:** Jacek Kubica: lecture fees from AstraZeneca, Bayer; Piotr Adamski: none; Jerzy R. Ładny: none; Jarosław Kaźmierczak: none; Tomasz Fabiszak: none; Krzysztof J. Filipiak: lecture fees from Adamed, AstraZeneca, Sanofi Aventis; Robert Gajda: none; Mariusz Gąsior: lecture fees from AstraZeneca; Zbigniew Gąsior: none; Robert Gil: none; Mariusz Gąsior: lecture fees from AstraZeneca; Zbigniew Gąsior: none; Robert Gil: none; Jarosław Gorący: lecture fees from AstraZeneca; Stefan Grajek: none; Leszek Gromadziński: none; Marcin Gruchala: none; Grzegorz Grześk: none; Piotr Hoffman: none; Miłosz J. Jaguszewski: speaking fees and travel grants from: Boheringer Ingelheim, Bayer, AstraZeneca, and Pfizer outside the submitted work; Marianna Janion: none; Piotr Jankowski: lecture fees, conference and scientific grants from: Amgen, Boehringer Ingelheim, KRKA, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Teva, Zentiva; Zbigniew Kalarus: none; Jarosław D.
3. Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute myocardial infarction in patients present¬ing with ST-segment elevation: The Task Force for the manage¬ment of acute myocardial infarction in patients present¬ing with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018; 39(2): 119–177, doi: 10.1093/eurheartj/ehx393, indexed in Pubmed: 28886621.

References

1. Kubica J, Adamski P, Paciorek P, et al. Anti-aggregation therapy in patients with acute coronary syndrome — recommendations for medical emergency teams. Experts’ standpoint. Kardiol Pol. 2017; 75(4): 399–408, doi: 10.5603/KPa2017.0057, indexed in Pubmed: 28421594.

2. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients present¬ing with ST-segment elevation: The Task Force for the manage¬ment of acute myocardial infarction in patients present¬ing with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018; 39(2): 119–177, doi: 10.1093/eurheartj/ehx393, indexed in Pubmed: 28886621.

3. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018; 39(3): 213–260, doi: 10.1093/eurheartj/ehx419, indexed in Pubmed: 28866622.

4. Kubica J, Adamski P, Paciorek P, et al. Treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams: Focus on antiplatelet therapies. Updated experts’ standpoint. Kardiol Pol. 2018; 25(3): 291–300, doi: 10.5603/CJ.a2018.0042, indexed in Pubmed: 29671864.

5. Collet JF; Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients present¬ing without persistent ST-segment elevation. Eur Heart J. 2021; 42(14): 1289–1367, doi: 10.1093/eurheartj/ehaa575, indexed in Pubmed: 32960058.

6. Borowitz A, Nadolny K, Bujak K, et al. Paramedic versus physician-staffed ambulances and prehospital delays in the manage¬ment of patients with ST-segment elevation myocardial infarction. Cardiol J. 2021; 28(1): 110–117, doi: 10.5603/CJ.a2019.0072, indexed in Pubmed: 31313723.

7. Lopes RD, Siha H, Fu Y, et al. Diagnosing acute myocardial infarction in patients with left bundle branch block. Am J Cardiol. 2011; 108(6): 782–788, doi: 10.1016/j.amjcard.2011.05.006, indexed in Pubmed: 21726838.

8. Chan AW, Kornder J, Elliott H, et al. Improved survival associ¬ated with pre-hospital triage strategy in a large regional ST-segment elevation myocardial infarction program. JACC Cardiovasc Interv. 2012; 5(12): 1239–1246, doi: 10.1016/j.jcin.2012.07.013, indexed in Pubmed: 22357372.

9. Widimsky P, Rohác F, Stásek J, et al. Primary angioplasty in acute myocardial infarction with right bundle branch block: should new onset right bundle branch block be added to future guidelines as an indication for reperfusion therapy? Eur Heart J. 2012; 33(1): 86–95, doi: 10.1093/eurheartj/ehr291, indexed in Pubmed: 21860488.

10. Dhurava VN, Abdelhadi SI, Anis A, et al. ST-Segment Analysis Using Wireless Technology in Acute Myocardial Infarction (STAT-MI) trial. J Am Coll Cardiol. 2007; 50(6): 509–513, doi: 10.1016/j.jacc.2007.04.049, indexed in Pubmed: 17678733.

11. Bagai A, Jolis JG, Dauerman HL, et al. Emergency department bypass for ST-Segment-elevation myocardial infarction patients identified with a prehospital electrocardiogram: a report from the American Heart Association Mission: Lifeline program. Circulation. 2013; 128(4): 352–359, doi: 10.1161/CIRCULATIONAHA.113.002338, indexed in Pubmed: 23798825.

12. Welsh RC, Chang W, Goldstein P, et al. Time to treatment and the impact of a physician on prehospital management of acute ST elevation myocardial infarction: insights from the ASSENT-3 PLUS trial. Heart. 2005; 91(11): 1400–1406, doi: 10.1136/hrt.2004.045410, indexed in Pubmed: 15774607.

13. Steg PG, James SK, Atar D, et al. ESC Guidelines for the manage¬ment of acute myocardial infarction in patients present¬ing with ST-segment elevation. Eur Heart J. 2012; 33(20): 2569–2619, doi: 10.1093/eurheartj/ehs4215, indexed in Pubmed: 22922416.

14. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients present¬ing without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndrome in Patients Present¬ing without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016; 37(3): 267–315, doi: 10.1093/eurheartj/ehs320, indexed in Pubmed: 26320110.

15. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet. 1995; 345(8951): 669–685, doi: 10.1016/s0140-6736(95)90986-x.

16. Parodi G. Editor’s Choice-Chest pain relief in patients with acute myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2016; 5(3): 277–281, doi: 10.1177/2048872615584078, indexed in Pubmed: 25904757.

17. Kubica J, Kubica A, Jilma B, et al. Impact of morphine on platelet effects of oral P2Y12 receptor inhibitors. Int J Cardiol. 2016; 215: 201–208, doi: 10.1016/j.ijcard.2016.04.077, indexed in Pubmed: 27128531.

18. Ostrowska M, Gorog D. Does morphine remain a standard of care in acute myocardial infarction? Med Res J. 2020; 5(1): 46–49, doi: 10.5603/mrj.a2020.0009.

19. Kubica J, Adamski P, Ostrowska M, et al. Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a randomized controlled trial. Trials. 2015; 16(3): 198–252, doi: 10.1186/s13063-015-0724-z, indexed in Pubmed: 25925591.

20. Hohl EL, Stimpfl T, Ebner J, et al. Morphine decreases clopi¬dogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2014; 63(7): 630–635, doi: 10.1016/j.jcicard.2013.10.068, indexed in Pubmed: 24315907.

21. Parodi G, Bellandi B, Xanthopoulou I, et al. Morphine is associ¬ated with a delayed activity of oral antiplatelet agents in patients with acute coronary syndrome.
with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv. 2015; 8(1), doi: 10.1161/CIRCINTERVENTIONS.114.001593, indexed in Pubmed: 25552595.

22. de Waha S, Eitel I, Desch S, et al. Intravenous morphine administration and reperfusion success in ST-elevation myocardial infarction: insights from cardiac magnetic resonance imaging. Clin Res Cardiol. 2015; 104(9): 727–734, doi: 10.1007/s00392-015-0835-2, indexed in Pubmed: 25725777.

23. Meine TJ, Roe MT, Chen AY, et al. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. Am Heart J. 2005; 149(6): 1043–1049, doi: 10.1016/j.ahj.2005.02.010, indexed in Pubmed: 15976786.

24. Poymirat E, Lambalt L, Bonnet N, et al. Correlates of pre-hospital morphine use in ST-elevation myocardial infarction patients and its association with in-hospital outcomes and long-term mortality: the FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) programme. Eur Heart J. 2016; 37(13): 1063–1071, doi: 10.1093/eurheartj/ehw867, indexed in Pubmed: 26578241.

25. Meine TJ, Roe MT, Chen AY, et al. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. Am Heart J. 2005; 149(6): 1043–1049, doi: 10.1016/j.ahj.2005.02.010, indexed in Pubmed: 15976786.

26. Jakobishvili Z, Porter A, Battler A, et al. Effect of narcotic treatment on outcomes of acute coronary syndromes. Am J Cardiol. 2010; 105(7): 912–916, doi: 10.1016/j.amjcard.2009.11.027, indexed in Pubmed: 20344305.

27. Goe YX, Sthinthakis N, Farag M, et al. Impact of preadministration morphine on reinfarction in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention: a meta-analysis. Clin Pharmacol Ther. 2020; 108(1): 54–62, doi: 10.1002/cpt.1798, indexed in Pubmed: 31990051.

28. Batchelor R, Liu DH, Bloom J, et al. Association of periprocedural intravenous morphine use on clinical outcomes in ST-elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention: Systematic review and meta-analysis. Catheter Cardiovasc Interv. 2020; 96(1): 76–88, doi: 10.1002/ccd.28561, indexed in Pubmed: 31654491.

29. Ibrahim K, Shah R, Goli RR, et al. Fentanyl delays the platelet inhibition effects of oral ticagrelor: Opioids and crushed Ticagrelor In Myo-elevation myocardial infarction patients: the MOJITO study. J Am Coll Cardiol. 2015; 65(5): 511–512, doi: 10.1016/j.jacc.2014.08.056, indexed in Pubmed: 25690931.

30. Rollini F, Franchi F, Angiolillo DJ, et al. Crushed prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary intervention: the CRUSH study. J Am Coll Cardiol. 2016; 67(17): 1994–2004, doi: 10.1016/j.jacc.2016.02.045, indexed in Pubmed: 27012781.

31. Niezgoda F, Sikora J, Barańska M, et al. Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina. A pharmacokinetic/pharmacodynamic study. Thromb Haemost. 2017; 117(4): 718–726, doi: 10.1161/THAHEM.118.006707, indexed in Pubmed: 26803084.

32. Tavenier AH, Hermanides RS, Ottervanger JP, et al. Impact of opioids on P2Y12 receptor inhibition in patients with ST-elevation myocardial infarction: insights from cardiac magnetic resonance imaging. Circulation. 2013; 127(5): 634–640, doi: 10.1161/CIRCULATIONAHA.112.113586, indexed in Pubmed: 23777394.

33. Adamski P, Adamska U, Ostrowska M, et al. New directions for pharmacotherapy in the treatment of acute coronary syndrome. Expert Opin Pharmacother. 2016; 17(17): 2291–2306, doi: 10.1080/14656566.2016.1241234, indexed in Pubmed: 27677394.

34. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361(11): 1045–1057, doi: 10.1056/NEJMoa0904327, indexed in Pubmed: 19717846.

35. Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation. 2013; 127(5): 634–640, doi: 10.1161/CIRCULATIONAHA.112.113586, indexed in Pubmed: 23777394.

36. Hansen ML, Sørensen R, Hansen M, Abildstrom S, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. The Lancet. 2009; 374(9706): 1967–1974, doi: 10.1016/s0140-6736(09)61751-7.

37. Oldgren J, Budaj A, Granger CB, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011; 32(22): 2781–2789, doi: 10.1093/eurheartj/ehr113, indexed in Pubmed: 21551462.

38. Tavyut T, Chaudhary R, Kubica J, et al. Cangrelor for the treatment of patients with Arterial Thrombosis. Expert Opin Pharmacother. 2015; 8(1), doi: 10.1165/circinterventions.2014.001593, indexed in Pubmed: 26972861.

39. Oldgren J, Budaj A, Granger CB, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011; 32(22): 2781–2789, doi: 10.1093/eurheartj/ehr113, indexed in Pubmed: 21551462.

40. Tavyut T, Chaudhary R, Kubica J, et al. Cangrelor for the treatment of patients with Arterial Thrombosis. Expert Opin Pharmacother. 2015; 8(1), doi: 10.1165/circinterventions.2014.001593, indexed in Pubmed: 26972861.

41. Oldgren J, Budaj A, Granger CB, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011; 32(22): 2781–2789, doi: 10.1093/eurheartj/ehr113, indexed in Pubmed: 21551462.

42. Tantry U, Chaudhary R, Kubica J, et al. Cangrelor for the treatment of patients with Arterial Thrombosis. Expert Opin Pharmacother. 2018; 19(12): 1389–1398, doi: 10.1080/14656566.2018.1506767, indexed in Pubmed: 30102083.
tery disease. Curr Med Res Opin. 2014; 30(5): 813–828, doi: 10.1185/03007995.2014.880059, indexed in Pubmed: 24390316.

46. Unniśka JM, Ratajczak J, Buszko K, et al. Impact of mild therapeutic hypothermia on bioavailability of ticagrelor in patients with acute myocardial infarction after out-of-hospital cardiac arrest. Cardiol J. 2020; 27(6): 780–788, doi: 10.5603/CJ.a2019.0024, indexed in Pubmed: 30799546.

47. Ratajczak J, Lach F, Unniśka JM, et al. Mild therapeutic hypothermia after out-of-hospital cardiac arrest: What does it really matter? Cardiol J. 2021; 28(2): 293–301, doi: 10.5603/CJ.a2019.0023, indexed in Pubmed: 30799547.

48. Tomala MT, Trąbka-Zawicki A, Machnik A, et al. Ticagrelor effectively inhibits platelet aggregation in comatose survivors of cardiac arrest undergoing primary percutaneous coronary intervention treated with mild therapeutic hypothermia. Cardiol J. 2021 [Epub ahead of print]; doi: 10.5603/CJ.a2021.0064, indexed in Pubmed: 34165181.

49. Directive of the Minister of Health dated 16 December 2019 on medical rescue procedures and health services different than medical rescue procedures, which can be performed by paramedic.

50. Montalescot G, van ’t Hof AW, Lapostolle F, et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med. 2014; 371(11): 1016–1027, doi: 10.1056/NEJMoa1407024, indexed in Pubmed: 25170921.

51. O'Donoghue M, Boden WE, Braunwald E, et al. Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. JAMA. 2008; 300(1): 71–80, doi: 10.1001/jama.300.1.71, indexed in Pubmed: 18594042.

52. Mehta SR, Cannon CP, Fox KAA, et al. Routine vs selective invasive strategies for unstable angina and non-ST-segment elevation acute coronary syndrome: a collaborative meta-analysis of randomized trials. JAMA. 2005; 293(23): 2908–2917, doi: 10.1001/jama.293.23.2908, indexed in Pubmed: 15956636.

53. Fox KAA, Clayton TC, Danman P, et al. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. J Am Coll Cardiol. 2010; 55(22): 2435–2445, doi: 10.1016/j.jacc.2010.03.007, indexed in Pubmed: 20359842.

54. Fanning JP, Nyong J, Scott IA, et al. Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent era. Cochrane Database Syst Rev. 2016(5): CD004815, doi: 10.1002/14651858.CD004815.pub1, indexed in Pubmed: 27226069.

55. Elgendy IY, Mahmoud AN, Wen X, et al. Meta-analysis of randomized trials of long-term all-cause mortality in patients with non-ST-elevation acute coronary syndrome managed with routine invasive versus selective invasive strategies. Am J Cardiol. 2017; 119(4): 560–564, doi: 10.1016/j.amjcard.2016.11.005, indexed in Pubmed: 27930385.

56. Schüpke S, Neumann FJ, Menichelli M, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med. 2019; 381(16): 1524–1534, doi: 10.1056/nejmoa1908973.

57. Kubica J, Jaguszewski M. ISAR-REACT 5 — What have we learned? Cardiol J. 2019; 26(5): 427–428, doi: 10.5603/CJ.a2019.0090, indexed in Pubmed: 31536136.

58. Angoulvant D, Sahouret D, Savage MP. NSTE-ACS ESC guidelines recommend prasugrel as the preferred P2Y12 inhibitor: a contrasting view. Am J Cardiovasc Drugs. 2021; 21(5): 483–486, doi: 10.1007/s40256-021-00471-z, indexed in Pubmed: 33674980.

59. Crea F, Thiele H, Sibbing D, et al. Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy. Eur Heart J. 2021; 42(31): 2973–2985, doi: 10.1093/eurheartj/ehab277, indexed in Pubmed: 34110420.

60. Arslan F, Danman P, Zwart B, et al. 2020 ESC Guidelines on acute coronary syndrome without ST-segment elevation: Recommendations and critical appraisal from the Dutch ACS and Interventional Cardiology working groups. Neth Heart J. 2021; 29(11): 557–565, doi: 10.1007/s12471-021-01593-4, indexed in Pubmed: 34232481.

61. Kubica J, Jaguszewski M, Ostrowska M, et al. Creative scientific dispute — different points of view on the protocol and execution of the ISAR-REACT 5 trial. Med Res J. 2020; 5(1): 41–45, doi: 10.5603/mrj.a2020.0008.

62. Navarese EP, Kuan SU, James S, et al. Comparative efficacy and safety of oral P2Y inhibitors in acute coronary syndrome: network meta-analysis of 52 816 patients from 12 randomized trials. Circulation. 2020; 142(2): 150–160, doi: 10.1161/CIRCULATIONA-HA.120.046786, indexed in Pubmed: 32488837.

63. Montalescot G, Bolognesi L, Dudek D, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013; 369(1): 999–1010, doi: 10.1056/NEJMoa1308075, indexed in Pubmed: 23991622.

64. Dowerc K, Redfors B, Angelos O, et al. Association of pretreatment with P2Y12 receptor antagonists preceding percutaneous coronary intervention in non-ST-segment elevation acute coronary syndromes with outcomes. JAMA Network Open. 2020; 3(10): e2018735, doi: 10.1001/jamanetworkopen.2020.18735, indexed in Pubmed: 33012002.

65. Tarantini G, Mojoli M, Varbella F, et al. Timing of oral P2Y inhibitor administration in patients with non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol. 2020; 76(2): 2450–2459, doi: 10.1016/j.jacc.2020.08.053, indexed in Pubmed: 32882390.

66. Gurbel PA, Blijden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009; 120(25): 2577–2585, doi: 10.1161/CIRCULATIONA-HA.109.912550, indexed in Pubmed: 19923168.

67. Buszko K, Kubica K, Hohl EL, et al. Pharmacokinetic modeling of morphine’s effect on plasma concentrations of ticagrelor and its metabolite in healthy volunteers. Front Physiol. 2021; 12: 663170, doi: 10.3389/fphys.2021.663170, indexed in Pubmed: 34248659.

68. Hohl EL, Reiter B, Schoenengerhofer C, et al. Morphine decreases ticagrelor concentrations but not its antiplatelet effects: a randomized trial in healthy volunteers. Eur J Clin Invest. 2016; 46(1): 7–14, doi: 10.1111/eci.12550, indexed in Pubmed: 26493388.

69. Hohl EL, Reiter B, Schoenengerhofer C, et al. Morphine interaction with prasugrel: a double-blind, cross-over trial in healthy volunteers. Clin Res Cardiol. 2016; 105(4): 349–355, doi: 10.1007/s00392-015-0927-z, indexed in Pubmed: 26493304.

70. Schoenengerhofer C, Hohl EL, Staudinger T, et al. Prasugrel in critically ill patients. Thromb Haemost. 2017; 117(8): 1582–1587, doi: 10.1160/TH17-03-0154, indexed in Pubmed: 28692105.

71. Adamski P, Sikora J, Laskowska E, et al. Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myo-
cardinal infarction: A prospective, observational, single-centre study. PLoS One. 2017; 12(10): e0186013, doi: 10.1371/journal.pone.0186013, indexed in Pubmed: 29023473.

72. Adamski P, Adamska U, Ostrowska M, et al. Evaluating current and emerging antithrombotic therapy currently available for the treatment of acute coronary syndrome in geriatric populations. Expert Opin Pharmacother. 2018; 19(13): 1415–1425, doi: 10.1080/14656666.2018.1510487, indexed in Pubmed: 30132731.

73. Ostrowska M, Kubica J, Adamski P, et al. Stratified approaches to antiplatelet therapies based on platelet reactivity testing. Front Cardiovasc Med. 2019; 6: 176, doi: 10.3389/fcvm.2019.00176, indexed in Pubmed: 31850573.

74. Kubica J, Adamski P, Gorog DA, et al. Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines. Cardiol J. 2020; 27(6): 661–676, doi: 10.5603/CJ.a2020.0132, indexed in Pubmed: 33073857.

75. Kubica J, Adamski P, Niezgoda P, et al. A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study. Cardiol J. 2021; 28(4): 607–614, doi: 10.5603/CJ.a2021.0056, indexed in Pubmed: 34096012.

76. Tubek S, Kuliczkowski W, Gąsior M, et al. Antiplatelets in acute coronary syndrome in Poland - from guidelines to clinical practice. Postepy Kardiol Interwencyjnej. 2021; 17(2): 141–154, doi: 10.3114/aic.2021.107492, indexed in Pubmed: 34409916.

77. Knutti J, Wijas W, Saraste A, et al. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020; 41(3): 407–477, doi: 10.1093/eurheartj/ehz425, indexed in Pubmed: 31504439.

78. Kubica J, Adamski P, Niezgoda P, et al. Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines. Cardiol J. 2020; 27(6): 661–676, doi: 10.5603/CJ.a2020.0132, indexed in Pubmed: 33073857.

79. Held C, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011; 57(6): 672–684, doi: 10.1016/j.jacc.2010.10.029, indexed in Pubmed: 21194870.

80. Barylski M, Legutko J, Lesiak M, et al. An expert opinion of the Association of Cardiovascular Interventions and the Working Group on Cardiovascular Pharmacotherapy of the Polish Cardiac Society related to the place of prasugrel in the prevention of cardiovascular events in patients with acute coronary syndromes. Kardiol Pol. 2022; 80(1): 113–122, doi: 10.33963/KPa2022.0006, indexed in Pubmed: 35076881.